JP7589143B2 - 神経可塑性を誘導するための方法および組成物 - Google Patents

神経可塑性を誘導するための方法および組成物 Download PDF

Info

Publication number
JP7589143B2
JP7589143B2 JP2021512444A JP2021512444A JP7589143B2 JP 7589143 B2 JP7589143 B2 JP 7589143B2 JP 2021512444 A JP2021512444 A JP 2021512444A JP 2021512444 A JP2021512444 A JP 2021512444A JP 7589143 B2 JP7589143 B2 JP 7589143B2
Authority
JP
Japan
Prior art keywords
stroke
cells
peptide
ptpσ
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021512444A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020051051A5 (https=
JP2021536461A5 (https=
JP2021536461A (ja
Inventor
シルバー，ジェリー
ルオ，ユ
ルオ，フーチェン
Original Assignee
ケース ウエスタン リザーブ ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケース ウエスタン リザーブ ユニバーシティ filed Critical ケース ウエスタン リザーブ ユニバーシティ
Publication of JP2021536461A publication Critical patent/JP2021536461A/ja
Publication of JPWO2020051051A5 publication Critical patent/JPWO2020051051A5/ja
Publication of JP2021536461A5 publication Critical patent/JP2021536461A5/ja
Priority to JP2024091680A priority Critical patent/JP2024113090A/ja
Application granted granted Critical
Publication of JP7589143B2 publication Critical patent/JP7589143B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2021512444A 2018-09-05 2019-08-29 神経可塑性を誘導するための方法および組成物 Active JP7589143B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024091680A JP2024113090A (ja) 2018-09-05 2024-06-05 神経可塑性を誘導するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862727420P 2018-09-05 2018-09-05
US62/727,420 2018-09-05
PCT/US2019/048698 WO2020051051A1 (en) 2018-09-05 2019-08-29 Methods and compositions for inducing neural plasticity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024091680A Division JP2024113090A (ja) 2018-09-05 2024-06-05 神経可塑性を誘導するための方法および組成物

Publications (4)

Publication Number Publication Date
JP2021536461A JP2021536461A (ja) 2021-12-27
JPWO2020051051A5 JPWO2020051051A5 (https=) 2022-09-06
JP2021536461A5 JP2021536461A5 (https=) 2022-09-06
JP7589143B2 true JP7589143B2 (ja) 2024-11-25

Family

ID=69722599

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021512444A Active JP7589143B2 (ja) 2018-09-05 2019-08-29 神経可塑性を誘導するための方法および組成物
JP2024091680A Pending JP2024113090A (ja) 2018-09-05 2024-06-05 神経可塑性を誘導するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024091680A Pending JP2024113090A (ja) 2018-09-05 2024-06-05 神経可塑性を誘導するための方法および組成物

Country Status (8)

Country Link
US (2) US12138300B2 (https=)
EP (1) EP3846838A4 (https=)
JP (2) JP7589143B2 (https=)
KR (1) KR102919967B1 (https=)
CN (1) CN113260373B (https=)
AU (1) AU2019334965B2 (https=)
CA (1) CA3111512A1 (https=)
WO (1) WO2020051051A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025092748A1 (zh) * 2023-11-01 2025-05-08 拜西欧斯（北京）生物技术有限公司 多肽衍生物、其药物组合物及其用途
WO2025169981A1 (ja) * 2024-02-07 2025-08-14 第一工業製薬株式会社 脳機能を改善するための環状ペプチド誘導体組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015516391A (ja) 2012-04-09 2015-06-11 ケース ウエスタン リザーブ ユニバーシティ Ｌａｒファミリーホスファターゼの活性を阻害する組成物及び方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2945108A1 (de) 1979-11-08 1981-05-21 Interatom Internationale Atomreaktorbau Gmbh, 5060 Bergisch Gladbach Faltenbalgkompensator
FR2641360B1 (fr) 1988-12-29 1991-02-22 Commissariat Energie Atomique Compensateur de dilatation monte entre deux tuyauteries
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
WO1995009656A1 (en) 1993-10-01 1995-04-13 New York University Novel receptor-type phosphotyrosine phosphatase-sigma
DE60023920T2 (de) 1999-08-27 2006-07-20 Sugen, Inc., South San Francisco Phosphatmimetika und Verfahren zur Behandlung mit Phosphataseinhibitoren HIBITOREN
EP1305333A4 (en) 2000-07-31 2006-04-12 Active Motif PEPTIDE-MEDIATED DELIVERY OF MOLECULES IN CELLS
WO2002083182A2 (en) 2001-04-12 2002-10-24 Mcgill University The effect of receptor protein tyrosine phosphatase sigma (rptp-$g(s)) on neural axon regeneration and synapse modification
US7829087B2 (en) 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
KR100814109B1 (ko) 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
US20090202544A1 (en) 2006-02-02 2009-08-13 The Trustees Of Columbia University In The City Of New York Methods of Treating Diseases by Targeting Silt3
KR100999043B1 (ko) 2007-12-04 2010-12-09 한국생명공학연구원 융합 단백질을 사용하지 않는 인간 단백질 타이로신탈인산화 효소의 활성 도메인 대량 생산 방법
WO2010129681A1 (en) 2009-05-05 2010-11-11 Van Andel Research Institute Methods for treating autophagy-related disorders
WO2010146058A1 (en) 2009-06-15 2010-12-23 Vib Vzw Bace1 inhibitory antibodies
WO2011022462A2 (en) 2009-08-18 2011-02-24 President And Fellows Of Harvard College Neural regeneration
WO2012019086A2 (en) 2010-08-06 2012-02-09 The University Of North Carolina At Chapel Hill Inhibition of lar phosphatase to enhance therapeutic angiogenesis
US9744188B2 (en) 2011-02-18 2017-08-29 President And Fellows Of Harvard College Methods of promoting neuronal outgrowth by gypican 2 that binds to receptor protein tyrosine phosphatase sigma
AU2013235422B2 (en) 2012-03-19 2016-12-15 Buck Institute For Research On Aging APP specific BACE inhibitors (ASBIs) and uses thereof
US20150084328A1 (en) 2013-09-24 2015-03-26 Witzenmann Gmbh Compensator arrangement

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015516391A (ja) 2012-04-09 2015-06-11 ケース ウエスタン リザーブ ユニバーシティ Ｌａｒファミリーホスファターゼの活性を阻害する組成物及び方法

Also Published As

Publication number Publication date
EP3846838A4 (en) 2022-06-08
EP3846838A1 (en) 2021-07-14
US12138300B2 (en) 2024-11-12
JP2024113090A (ja) 2024-08-21
KR102919967B1 (ko) 2026-01-30
WO2020051051A1 (en) 2020-03-12
CN113260373A (zh) 2021-08-13
US20250255939A1 (en) 2025-08-14
AU2019334965A1 (en) 2021-03-25
AU2019334965B2 (en) 2025-01-23
KR20210054542A (ko) 2021-05-13
CA3111512A1 (en) 2020-03-12
CN113260373B (zh) 2025-04-22
JP2021536461A (ja) 2021-12-27
US20210330757A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
JP7829511B2 (ja) Ｌａｒファミリーホスファターゼの活性を阻害する組成物及び方法
US20250255939A1 (en) Methods and compositions for inducing neural plasticity
JP2019501210A (ja) 神経細胞の損失予防及び再生の効能を有するペプチド及びこれを含む組成物
JP2023537318A (ja) 中枢神経系障害の処置のためのキメラタンパク質および使用方法
Tsai et al. (+)-Naloxone inhibits morphine-induced chemotaxis via prevention of heat shock protein 90 cleavage in microglia
US9073976B2 (en) ND2 peptides and methods of treating neurological disease
US10160791B2 (en) Protamine in treatment of neuronal injuries
JP5784754B2 (ja) 神経疾患の予防または処置のためのｉｃａｍ−１の使用
US20090291887A1 (en) Proteins of the SDF-1-Family for the Manufacturing of a Medicament
RU2575570C2 (ru) Применение нейрегулина для лечения повреждения периферических нервов
HK1187931B (en) Nd2 peptides and methods of treating neurological disease
HK1187931A (en) Nd2 peptides and methods of treating neurological disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220829

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240606

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241022

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241113

R150 Certificate of patent or registration of utility model

Ref document number: 7589143

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150